• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Network Meta-Analysis Ranks Garadacimab Highest for Preventing Hereditary Angioedema Attacks

by
November 13, 2026
in Health
Reading Time: 6 mins read
0
Network Meta-Analysis Ranks Garadacimab Highest for Preventing Hereditary Angioedema Attacks

Network Meta-Analysis Ranks Garadacimab Highest for Preventing Hereditary Angioedema Attacks

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Garadacimab demonstrated superior efficacy over multiple existing prophylactic therapies for hereditary angioedema in a Bayesian network meta-analysis published in Drugs in R&D. The comprehensive synthesis, conducted by Sarah Walsh and colleagues, evaluated randomized controlled trials to establish comparative efficacy, safety profiles, and patient-reported outcomes across licensed and investigational long-term preventative regimens. Hereditary angioedema is a rare autosomal-dominant genetic disorder characterized by recurring swelling episodes affecting skin, abdomen, limbs, face, and airways. In patients with type 1 or type 2 hereditary angioedema, deficiency or dysfunction of C1 esterase inhibitor triggers excessive accumulation of bradykinin, leading directly to abnormal vasodilation and increased vascular permeability. Because head-to-head clinical trials comparing modern preventative treatments have never been conducted, decision-makers have lacked comparative evidence. To resolve this evidence gap, investigators implemented indirect comparison techniques across contemporary placebo-controlled trials, assessing garadacimab alongside lanadelumab, subcutaneous C1 esterase inhibitor, and berotralstat in patients aged twelve and older.

Approved by the European Medicines Agency in February 2025 and awaiting United States Food and Drug Administration review, garadacimab represents an emerging prophylactic option. The analysis compared this agent against established first-line options, including lanadelumab, a monoclonal antibody targeting plasma kallikrein, evaluated across dosing intervals of 300 milligrams every two weeks and 300 milligrams every four weeks. The comparative network also incorporated a plasma-derived subcutaneous C1 esterase inhibitor formulation administered at 60 international units per kilogram twice weekly, alongside berotralstat, an oral plasma kallikrein inhibitor prescribed at 150 milligrams daily. While each agent previously demonstrated significant attack reductions compared with placebo in registration trials, their relative comparative therapeutic rankings remained unclarified.

To identify clinical trials informing the network, the research team conducted a systematic literature review in strict accordance with the Preferred Reporting Items for Systematic Literature Reviews and Meta-Analyses guidelines. The protocol was registered prospectively in the International Prospective Register of Systematic Reviews under code CRD42022359207. Database searches conducted on August 11, 2022, and updated on September 16, 2024, identified randomized controlled trials evaluating prophylaxis in patients at least twelve years old. A qualitative feasibility assessment was conducted to confirm the exchangeability assumption, ensuring evaluated interventions could theoretically have been directly compared without introducing bias. Following recommended methodological guidelines, investigators evaluated between-trial heterogeneity in study designs, populations, and outcome measures. With validation from clinical experts, post-crossover data from the COMPACT study and its extension, parts two and three of the APeX-J trial, and treatment period two from the phase II garadacimab trial were excluded, leaving seven trials deemed sufficiently similar for evidence synthesis.

The statistical framework used Bayesian evidence synthesis methods outlined by the National Institute for Health and Care Excellence Evidence Synthesis Decision Support Unit. Because the resulting evidence networks were sparse and informed by few trials, fixed-effect models were selected a priori as the primary analytical base case. A zero-cell correction was implemented for trials reporting zero event outcomes to maintain computational stability. Count-based rate outcomes were evaluated using Poisson regression models with log link functions and exposure-time offsets, generating rate ratios with 95 percent credible intervals. For dichotomous outcomes, including attack-free proportions and adverse event rates, binomial models with complementary log-log links and maximum follow-up offsets were used to calculate hazard ratios. Quality-of-life adjustments were estimated using normal models with identity link functions to calculate mean differences. Markov Chain Monte Carlo algorithms executed in R, JAGS, and WinBUGS utilized 20,000 to 60,000 iterations, with comparative hierarchies defined by probability of being best and cumulative ranking curve percentages.

For the primary efficacy outcome of time-normalized hereditary angioedema attacks, the network comprised six placebo-controlled trials across five active treatment nodes. The fixed-effect Bayesian analysis established that all five active regimens—garadacimab monthly, biweekly lanadelumab, subcutaneous C1 inhibitor, four-week lanadelumab, and berotralstat—achieved statistically significant reductions in attack rates compared to placebo. Relative effect estimates revealed that garadacimab achieved statistically significant rate reductions compared with every competing prophylactic therapy except biweekly lanadelumab. Lanadelumab dosed every two weeks also produced statistically significant reductions relative to lanadelumab every four weeks, berotralstat, and placebo. In cumulative hierarchy calculations, garadacimab achieved a 73 percent probability of being the most effective therapy and a 94 percent surface under the cumulative ranking curve score. Lanadelumab dosed every two weeks ranked second across the network, demonstrating a 26 percent probability of being best alongside an 83 percent cumulative ranking score.

The proportion of patients achieving complete freedom from angioedema attacks represented a key secondary endpoint, assessed across five placebo-controlled trials. The APeX-J trial was excluded because zero patients in either arm achieved attack-free status, contributing no evidence under binomial modeling. In the fixed-effect synthesis, garadacimab, lanadelumab every two weeks, lanadelumab every four weeks, and subcutaneous C1 inhibitor each demonstrated statistically significant increases in attack-free rates compared with placebo. However, relative comparisons between active drugs did not achieve statistical significance. Despite overlapping credible intervals, garadacimab demonstrated the highest numerical probability of superiority, recording a 55 percent probability of being the most effective therapy and an 83 percent cumulative ranking score, with biweekly lanadelumab ranking second at 28 percent and 77 percent, respectively. The investigators noted that this modeled parity contrasted with published raw trial observations reporting attack-free rates of 62 percent for garadacimab, 44.4 percent for biweekly lanadelumab, 31 percent for monthly lanadelumab, and 5 percent for berotralstat.

Further efficacy evaluations examined the frequency of attacks requiring acute on-demand treatment and the rate of moderate or severe swelling events. In the analysis of on-demand therapy across six placebo-controlled trials, all active regimens significantly reduced acute treatment requirements compared with placebo. Pairwise comparisons revealed that garadacimab significantly reduced on-demand-treated attack rates compared with monthly lanadelumab and berotralstat, while subcutaneous C1 inhibitor also demonstrated statistically significant reductions over both comparators. Garadacimab ranked first with a 53 percent probability of being best and an 88 percent cumulative ranking score, followed by subcutaneous C1 inhibitor at 35 percent and 82 percent, respectively. In the analysis of moderate-to-severe attacks, garadacimab achieved its most decisive separation, showing a statistically significant reduction in attack rates compared with every other comparator. For this endpoint, garadacimab attained a 98 percent probability of being best and a 100 percent cumulative ranking score, while subcutaneous C1 inhibitor ranked second with a 1 percent probability and a 74 percent score.

Safety outcomes were evaluated through the incidence of treatment-emergent adverse events across five placebo-controlled trials, with APeX-J excluded because 100 percent of participants in both arms experienced adverse events. In the fixed-effect Bayesian synthesis, most active therapies exhibited higher adverse event rates than placebo, with lanadelumab dosed every two weeks emerging as the only drug demonstrating a statistically significant increase in adverse events compared to placebo. Subcutaneous C1 inhibitor was the only active intervention favored over placebo in reducing adverse events, though this difference did not reach statistical significance. In relative comparisons, subcutaneous C1 inhibitor significantly reduced adverse events compared with biweekly lanadelumab. Reflecting this favorable profile, subcutaneous C1 inhibitor recorded the highest likelihood of safety superiority among active agents, capturing a 56 percent probability of being the most effective treatment for minimizing adverse events and an 82 percent cumulative ranking score, with placebo ranking second at 17 percent and 75 percent, respectively.

The investigators also analyzed patient-reported quality of life across four placebo-controlled trials reporting changes from baseline in the angioedema quality-of-life total score. The fixed-effect analysis showed that garadacimab, lanadelumab every two weeks, and lanadelumab every four weeks each produced statistically significant improvements in quality of life compared to placebo, whereas berotralstat was the only active intervention failing to show significant improvement over placebo. Direct network comparisons demonstrated that garadacimab achieved a statistically significant improvement in quality of life over berotralstat, producing an estimated seventeen-point score reduction exceeding the established minimal clinically important difference of six points required for patients to perceive meaningful change. Garadacimab achieved an 85 percent probability of being the most effective therapy for improving quality of life alongside a 95 percent cumulative ranking score.

The authors discussed notable methodological strengths and inherent analytical limitations that contextualize the study findings. The investigation strictly followed best-practice reporting guidelines, including the PRISMA extension for network meta-analyses, and relied on an extensive literature search peer-reviewed by information specialists. Quality assessment using the Centre for Reviews and Dissemination checklist confirmed that all included trials demonstrated high quality across randomization, blinding, and allocation. However, the resulting evidence networks were sparse and predominantly informed by single trials connecting active treatments solely through shared placebo comparators rather than direct head-to-head investigations. This sparse structural topology increased the potential for biased effect estimates and precluded meta-regression to control for inter-trial heterogeneity. Furthermore, incorporating certain comparators necessitated compromises, such as restricting subcutaneous C1 inhibitor data from the COMPACT study to sixteen weeks of pre-crossover exposure. Variations in attack definitions between protocols also represented potential residual heterogeneity, underscoring that indirect synthesis estimates provide one valuable decision-making tool that clinicians must balance alongside individual patient preferences and clinical expertise.

Subject of Research: Comparative efficacy, safety, and quality-of-life outcomes of long-term prophylactic pharmacological therapies for hereditary angioedema.

Article Title: Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema

Article References: Walsh, S., Bartlett, M., Salvo-Halloran, E. M., Sears, J., Li, Y., Kelly, M., Gavata-Steiger, S., Nenci, C., Jacobs, I., Pragst, I., Ray, N., & Samjoo, I. A. (2025). Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema. Drugs in R&D, 25(2), 161-178. https://doi.org/10.1007/s40268-025-00511-y

Image Credits: AI Generated

DOI: 10.1007/s40268-025-00511-y

Keywords: hereditary angioedema, garadacimab, lanadelumab, berotralstat, subcutaneous C1 inhibitor, network meta-analysis, long-term prophylaxis, C1 esterase inhibitor deficiency, bradykinin, factor XII inhibition, plasma kallikrein, angioedema attack rate, AE-QoL score, treatment-emergent adverse events, Bayesian evidence synthesis, SUCRA ranking, on-demand therapy reduction, placebo-controlled trials

News Source: Ophelia Keating. (November 13, 2026). Network Meta-Analysis Ranks Garadacimab Highest for Preventing Hereditary Angioedema Attacks. Scienmag.

Tags: AE-QoL scoreangioedema attack rateBayesian evidence synthesisberotralstatbradykininC1 esterase inhibitor deficiencyfactor XII inhibitiongaradacimabhereditary angioedemalanadelumablong-term prophylaxisNetwork Meta-Analysison-demand therapy reductionplacebo-controlled trialsplasma kallikreinsubcutaneous C1 inhibitorSUCRA rankingtreatment-emergent adverse events
Share12Tweet7Share2ShareShareShare1

Related Posts

Genomic Modeling Uncovers Key Variants and Shared Architecture Underlying Mania Liability

Genomic Modeling Uncovers Key Variants and Shared Architecture Underlying Mania Liability

November 17, 2026
Salvage Hysterectomy Outcomes Following Definitive Radiotherapy for Cervical Cancer

Salvage Hysterectomy Outcomes Following Definitive Radiotherapy for Cervical Cancer

November 17, 2026

Manganese Poses Highest Contamination Risk in Northern Hainan Coastal Groundwater

November 17, 2026

Lipid Nanoparticles Offer Precision Delivery for Hard-to-Treat Invasive Fungal Infections

November 17, 2026

POPULAR NEWS

  • Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    29 shares
    Share 12 Tweet 7
  • Serum Mass Spectrometry Predicts Treatment Response in HER2-Positive Breast Cancer

    29 shares
    Share 12 Tweet 7
  • Polypharmacy Linked to Higher Odds of Sarcopenia in Older Adults

    29 shares
    Share 12 Tweet 7
  • Adapted Virtual Presence Tool Proves Feasible in Pilot Manikin Simulation Courses

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Genomic Modeling Uncovers Key Variants and Shared Architecture Underlying Mania Liability

Salvage Hysterectomy Outcomes Following Definitive Radiotherapy for Cervical Cancer

Drug-Controlled RNA Switch Regulates Therapeutic Protein Production in Preclinical Gene Therapy

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.